Hepatitis B, a viral infection that attacks the liver causing cirrhosis and hepatocellular carcinoma among other life-threatening complications, took 887,000 lives in 2015 alone. HBV is a major global health problem with about 257 million people living with hepatitis B infection. About 7.4% of HIV-infected also have HBV.
Hepatitis B infection can be acute or chronic, the latter being treated with medicines, including oral antiviral agents which can improve long term survival. The treatment, however, does not cure hepatitis B infection, but only suppresses the replication of the virus. Therefore, the majority of people with chronic HBV must continue their treatment for life.
Hepatitis B prevalence is the highest in the WHO Western Pacific Region and the WHO African Region, with 6.2% and 6.1% respectively of the adult population living with the infection.
NUMBER OF PEOPLE INFECTED WITH HBV AND PERCENTAGE OF ALL PEOPLE LiVING WITH HBV IN LOW- AND MIDDLE-INCOME COUNTRIES OVERALL BY WHO REGION 2017*
Viriom's Global Antiviral Platform gives HBV-infected in low-income counties around the globe the hope for safer and more effective treatment alternatives that they would have not been able to afford otherwise. Learn more about our platform and how Viriom delivers its promise of Hope, Health, and Happiness for all.